Abiopharma

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

(63% Neutral) REPLIGEN CORP (RGEN) Files Form 8-K

(75% Positive) KALA BIO, Inc. (KALA) Files Form 8-K

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

PMGC Holdings Inc. Announces Strategic Share Acquisition in Micro Modular Reactor (MMR) Focused Nuclear Energy Company, Nuclea Energy Inc.

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

(30% Negative) AngioDynamics, Inc. (ANGO) Reports Q1 2026 Financial Results

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

(70% Positive) Aclaris Therapeutics, Inc. (ACRS) Provides Update on Expected for immuno-inflammatory diseases